Acta Haematologica最新文献

Treatment of Philadelphia positive acute lymphoblastic leukemia. 费城阳性急性淋巴细胞白血病的治疗。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-24 DOI: 10.1159/000547026

Anna Torrent, Josep Maria Ribera

{"title":"Treatment of Philadelphia positive acute lymphoblastic leukemia.","authors":"Anna Torrent, Josep Maria Ribera","doi":"10.1159/000547026","DOIUrl":"https://doi.org/10.1159/000547026","url":null,"abstract":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has historically been associated with poor prognosis and limited therapeutic options. Over the past two decades, however, the treatment paradigm has markedly shifted. The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and ponatinib, has revolutionized frontline therapy, significantly improving remission rates and long-term survival. These agents, when combined with reduced-intensity chemotherapy or even with corticosteroids, have enabled less toxic regimens, particularly beneficial for older or unfit patients. The implementation of measurable residual disease (MRD) monitoring has emerged as a pivotal tool for risk stratification and therapeutic decision-making. Consequently, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), considered a cornerstone of curative treatment, is being re-evaluated in patients achieving sustained deep molecular responses. More recently, immunotherapeutic strategies-including the bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR) T-cell therapies-have emerged as effective alternatives to conventional chemotherapy and TKIs. This review outlines the major advances in the management of Ph+ ALL, emphasizing the move toward more personalized, targeted, and less toxic treatment approaches.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-22"},"PeriodicalIF":1.7,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in Hemophilia Management: Revolutionizing Patient Care and Future Directions. 血友病管理中的人工智能：革命性的患者护理和未来方向。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-24 DOI: 10.1159/000546954

Sarina Levy-Mendelovich, Benjamin S Glicksberg, Shelly Soffer, Moran Gendler, Orly Efros, Eyal Klang

引用次数: 0

Identification of needs of patients with multiple myeloma: a questionnaire-based study in Israeli patients. 确定多发性骨髓瘤患者的需求：一项基于问卷的以色列患者研究。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-24 DOI: 10.1159/000547025

Ilana Levy Yurkovski, Shira Ben-Dov, Varda Shoam, Micha Yuz, Noa Lavi

{"title":"Identification of needs of patients with multiple myeloma: a questionnaire-based study in Israeli patients.","authors":"Ilana Levy Yurkovski, Shira Ben-Dov, Varda Shoam, Micha Yuz, Noa Lavi","doi":"10.1159/000547025","DOIUrl":"https://doi.org/10.1159/000547025","url":null,"abstract":"Purpose: Multiple myeloma is an incurable chronic malignant disease. The disease itself and its treatment impair quality-of-life (QoL), yet there is no data regarding the biopsychosocial needs of patients in the era of new treatments. In the current study, we aimed to identify the biopsychosocial needs of patients with multiple myeloma.Methods: This is a descriptive study on patients with multiple myeloma in Israel in 2024. The information was based on a questionnaire examining physical, psychological and social needs filled out by myeloma patients. We analyzed the main impairments of QoL and what affected them, the main supporter in dealing with the disease, psychosocial needs reported by the patients and the difficulties in dealing with such difficulties.Results: The main symptom reported by multiple myeloma patients was fatigue. The number of treatment lines worsened QoL (Unstandardized coefficient: 0.987, 95% CI: 0.284; 1.691, p=0.006). The patient's partner mostly helped in dealing with the disease (72.7%). The most desired type of support was assistance in accessing rights (median 5, IQR 3-5), however one third did not use the support services offered to them. 48% of the patients talked to their doctor about the struggle and the accompanying difficulties.Conclusion: Myeloma patients report various impairments in the biopsychosocial components of QoL. Although supportive services are offered, adjustments must be made to optimally meet patients' needs. Further studies should test the effectiveness of different interventions on the biopsychosocial components of the QoL of these patients in the era of new drugs.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-15"},"PeriodicalIF":1.7,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning application for bleeding risk prediction in patients with atrial fibrillation treated with oral anticoagulation. 机器学习在口服抗凝治疗心房颤动患者出血风险预测中的应用。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-13 DOI: 10.1159/000546663

Tsahi T Lerman, Shmuel Tiosano, Roy Beigel, Michal Cohen-Shelly, Ran Kornowski, Refael Munitz, David A Nace, Shuja Hassan, Karen Scandrett, Daniel E Forman, Boris Fishman

{"title":"Machine learning application for bleeding risk prediction in patients with atrial fibrillation treated with oral anticoagulation.","authors":"Tsahi T Lerman, Shmuel Tiosano, Roy Beigel, Michal Cohen-Shelly, Ran Kornowski, Refael Munitz, David A Nace, Shuja Hassan, Karen Scandrett, Daniel E Forman, Boris Fishman","doi":"10.1159/000546663","DOIUrl":"https://doi.org/10.1159/000546663","url":null,"abstract":"Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with a significantly increased risk of systemic thromboembolism and stroke. Anticoagulation therapy, particularly with Direct Oral Anticoagulants, has become the standard for stroke prevention but comes at the cost of an increased bleeding risk. With the introduction of effective alternatives to anticoagulation, such as percutaneous left atrial appendage occlusion, bleeding risk stratification has become essential to guide therapeutic decision-making. Conventional statistical methods have been used for bleeding risk stratification scores, such as HEMORR2HAGES, HAS-BLED, and ATRIA. However, these methods may inadequately address the multifactorial nature of bleeding risk in diverse patient populations, and their overall performance has been suboptimal. Recent advancements in machine learning (ML) offer promising opportunities to enhance bleeding risk prediction and optimize anticoagulation therapy. This review explores ML applications in AF patients receiving anticoagulation therapy, focusing on the development and validation of ML-based bleeding risk scores. These models have demonstrated improved predictive performance compared to traditional tools, leveraging complex datasets to identify nuanced patterns and interactions. Furthermore, ML-driven tools in warfarin management, including dose prediction, optimization of time in the therapeutic range, and the identification of drug-drug interactions, show significant potential to enhance patient safety and treatment efficacy.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-16"},"PeriodicalIF":1.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144300938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating AI into Hematology: New Frontiers and Practical Applications. 将人工智能整合到血液学：新领域和实际应用。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-13 DOI: 10.1159/000546889

Shelly Soffer, Eyal Klang

引用次数: 0

Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy. 髓系肿瘤患者的环染色体与治疗不良反应相关。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-12 DOI: 10.1159/000546757

Daniel I Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Bridget K Marcellino, Douglas Tremblay, Lewis R Silverman, Vesna Najfeld, Jonathan Feld

{"title":"Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy.","authors":"Daniel I Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Bridget K Marcellino, Douglas Tremblay, Lewis R Silverman, Vesna Najfeld, Jonathan Feld","doi":"10.1159/000546757","DOIUrl":"https://doi.org/10.1159/000546757","url":null,"abstract":"Introduction: Ring chromosomes (RC) are acquired circular structural abnormalities associated with gain or loss of genetic material, which are thought to be associated with inferior outcomes of patients with myeloid neoplasms (MN). The responses of patients with MN and RC to the standard therapeutic options have not been reported previously.Methods: We analyzed the demographics and outcomes of 31 consecutive patients with MN and RC and compared median overall survival (mOS) and progression-free survival (PFS) of patients who received supportive care (n = 9), cytotoxic chemotherapeutic options (n = 3), hypomethylating agents (HMA) alone (n = 6), or HMA in combination with venetoclax (n = 13).Results: Over 60% of all patients with RC had either a TP53 mutation, loss of 17p, or both. Interestingly, 22/31 (71%) of patients did not receive prior radiation or chemotherapy. Patients who received supportive care had a shorter mOS (p = 0.001), but none of the therapeutic interventions were associated with further improvement in prolonging mOS (p = 0.86) or PFS. The presence of a complex karyotype, TP53 mutations/loss of TP53, or a treatment-related MN was not independently associated with an inferior OS in MN patients with RC.Conclusion: These findings indicate the patients with MN and RC have especially poor outcomes, and that effective treatment strategies remain an unmet need.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-17"},"PeriodicalIF":1.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. 老年人新诊断费城染色体阴性急性淋巴细胞白血病的治疗。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-06-10 DOI: 10.1159/000546381

Lourdes M Mendez, Daniel J DeAngelo, Marlise R Luskin

{"title":"Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.","authors":"Lourdes M Mendez, Daniel J DeAngelo, Marlise R Luskin","doi":"10.1159/000546381","DOIUrl":"https://doi.org/10.1159/000546381","url":null,"abstract":"Approximately half of newly diagnosed cases of acute lymphoblastic leukemia (ALL) occur in adults, but adults experience significantly higher rates of treatment failure and treatment-related mortality due to frequent presence of adverse disease biology and limited tolerability of conventional chemotherapy. Here, we discuss recent data from clinical trials investigating new approaches for initial treatment of Philadelphia chromosome-negative ALL in older adults. These trials investigate the incorporation of novel agents including the anti-CD22 antibody-drug conjugate inotuzumab, the CD19-CD3 bi-specific T-cell engager blinatumomab, and the BCL2 inhibitor venetoclax into treatment regimens, with some studies attenuating or omitting chemotherapy. We also discuss the role of allogeneic stem cell transplantation consolidation for this population and highlight the possibility of front-line CD19-directed CAR-T consolidation approaches for B-ALL. Finally, we discuss improved understanding of the genetic diversity of ALL in older adults including occurrence of ALL with TP53 mutation, ALL with myeloid gene mutations, and therapy-related ALL. Overall, we highlight progress for older adults with Ph-negative ALL with patients more frequently achieving a measurable-residual disease negative complete remission, but significant work remains to improve the safety of treatment as well as the depth and durability of treatment response.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-22"},"PeriodicalIF":1.7,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasonography-Guided Core-Needle Biopsy for Newly Diagnosed Large B-Cell Lymphomas: Analysis on Diagnostic Efficacy and Safety in an Italian Retrospective Study. 超声引导下的芯针活检对新诊断的大b细胞淋巴瘤：意大利回顾性研究的诊断有效性和安全性分析。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-05-26 DOI: 10.1159/000544794

Marco Picardi, Claudia Giordano, Annamaria Vincenzi, Novella Pugliese, Alessia Scarpa, Massimo Mascolo, Elena Vigliar, Giancarlo Troncone, Claudia Salvatore, Fabrizio Pane

{"title":"Ultrasonography-Guided Core-Needle Biopsy for Newly Diagnosed Large B-Cell Lymphomas: Analysis on Diagnostic Efficacy and Safety in an Italian Retrospective Study.","authors":"Marco Picardi, Claudia Giordano, Annamaria Vincenzi, Novella Pugliese, Alessia Scarpa, Massimo Mascolo, Elena Vigliar, Giancarlo Troncone, Claudia Salvatore, Fabrizio Pane","doi":"10.1159/000544794","DOIUrl":"10.1159/000544794","url":null,"abstract":"Introduction: Excisional biopsy (EB) is the gold standard for large B-cell lymphomas (LBCLs) diagnosis. Based on recent advances in interventional radiology enabling accurate sampling with core needle biopsy (CNB), we evaluated efficacy and safety of CNB under imaging guidance for diagnosing LBCLs.Methods: At the Hematology and Pathology Units of the Federico II University Medical School of Naples (Italy), we retrospectively collected patients with lymphadenopathies suspected of lymphomas (during 2009-2022) of which the ultrasonography (US)-guided CNB lymph node samples were available. Subsequently, we investigated the accuracy and safety of US-guided CNB for LBCLs diagnosis.Results: Over a 12-year period, 800 (superficial target, n = 560; deep-seated target, n = 240) lymph node biopsies performed with 16-gauge diameter modified Menghini needle under power-Doppler ultrasonographic guidance have been evaluated in 800 patients. According to the reference standard, 220 were suffering from LBCLs (diffuse LBCL NOS [n = 196], and high-grade B-cell lymphoma with MYC and BCL2 rearrangements [n = 24]) subtypes, other malignancy subtypes (n = 510) and non-malignant findings (n = 70). For the series of LBCLs, the overall diagnostic accuracy of the micro-histological sampling was 100% (95% confidence interval: 98%-100%). The complications occurred with very low incidence and severity (grade ≤2).Conclusion: US-guided CNB is a less invasive method and can be considered an alternative to EB for LBCL diagnosis.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI Applications in Transfusion Medicine: Opportunities, Challenges, and Future Directions. 人工智能在输血医学中的应用：机遇、挑战和未来方向。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-05-09 DOI: 10.1159/000546303

Merav Barzilai, Omri Cohen

{"title":"AI Applications in Transfusion Medicine: Opportunities, Challenges, and Future Directions.","authors":"Merav Barzilai, Omri Cohen","doi":"10.1159/000546303","DOIUrl":"10.1159/000546303","url":null,"abstract":"Background: Artificial intelligence (AI) is reshaping healthcare, with its applications in transfusion medicine (TM) showing great promise to address longstanding challenges.Summary: This review explores the integration of AI-driven tools, including machine learning, deep learning, natural language processing, and predictive analytics, across various domains of TM. From enhancing donor management and optimizing blood product quality to predicting transfusion needs and assessing bleeding risks, AI has demonstrated its potential to improve operational efficiency, patient safety, and resource allocation. Additionally, AI-powered systems enable more accurate blood antigen phenotyping, automate hemovigilance workflows, and streamline inventory management through advanced forecasting models. While these advancements are largely exploratory, early studies highlight the growing importance of AI in improving patient outcomes and advancing precision medicine. However, challenges such as variability in clinical workflows, algorithmic transparency, equitable access, and ethical concerns around data privacy and bias must be addressed to ensure responsible integration.Key messages: (i) AI-driven tools are being applied across multiple domains of TM. (ii) Early studies demonstrate the potential for AI to improve efficiency, safety, and personalization. (iii) Key implementation challenges include data privacy, workflow integration, and equitable access.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia. 超越细胞疗法：抗体驱动的免疫疗法在儿童急性淋巴细胞白血病中的扩展作用。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-05-05 DOI: 10.1159/000546249

David McCall, Samanta Catueno, Ramya Ramakrishnan, Priti Tewari, Irtiza Sheikh, Amber Gibson, Cesar A Nuñez, Miriam B Garcia, Branko Cuglievan

{"title":"Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia.","authors":"David McCall, Samanta Catueno, Ramya Ramakrishnan, Priti Tewari, Irtiza Sheikh, Amber Gibson, Cesar A Nuñez, Miriam B Garcia, Branko Cuglievan","doi":"10.1159/000546249","DOIUrl":"10.1159/000546249","url":null,"abstract":"Background: The integration of novel antibody-mediated targeted therapies into both relapsed/refractory (R/R) and frontline pediatric acute lymphoblastic leukemia (ALL) treatment protocols has led to critical advancements in the field. Current research efforts focus on optimizing targeted therapies to enhance precision and efficacy while minimizing toxicity by reducing chemotherapy. A notable example is the addition of blinatumomab, demonstrating superiority over conventional chemotherapy, with an 8% increase in disease-free survival at an interim analysis, reaching 96%. Inotuzumab ozogamicin (InO) has also shown promise, achieving nearly a 70% complete response rate in pediatric R/R B-cell ALL (B-ALL) trials. Additionally, daratumumab in T-cell ALL (T-ALL) and chimeric antigen receptor T-cell therapies, particularly CD19-directed (B-ALL) and CD7-directed (T-ALL) strategies, are under active investigation.Summary: This review will provide an overview of targeted antibody-mediated immunotherapies in both B-ALL and T-ALL, with a focus on their pediatric applications, supporting data, and future prospects.Key messages: The next cycle of frontline trials in pediatric ALL will incorporate more immunotherapy with reduction of chemotherapy. Subsequent trials will utilize more concurrent chemoimmunotherapy blocks as precision testing and risk-adapted therapy will continue to develop. These advancements reflect a paradigm shift toward more precise, less toxic treatment strategies in pediatric ALL.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-16"},"PeriodicalIF":1.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0